LR Health & Beauty Builds Most Modern Aloe Vera Production Plant in Europe
LR Health & Beauty continues to grow and is expanding its production capacities. The most modern production facility for LR Aloe Vera products in Europe is being built at the headquarters of the network marketing company in Ahlen (Westphalia, Germany) until December 2017. LR invests EUR 4.5 million in high-tech machinery alone and underscores its leading position in the production and marketing of first-class Aloe Vera products, which are distributed by LR sales partners.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170904005020/en/
Model view of the new Aloe Vera production site of LR Health & Beauty. Copyright: Assmann Group/LR
The new Aloe Vera production plant is part of LR’s sustainable growth strategy. On an area of approx. 4,000 m2, the popular LR Aloe Vera Drinking Gels, of which LR has sold more than 55 million litres since 2002, will be produced and dispatched starting from the end of the year. “Aloe Vera products are one of the core competencies of LR. We have made Aloe Vera popular in Germany and boast the most extensive know-how in this area. To meet the increasing demand by our sales partners, we are expanding our production capacities in Ahlen,” explained Dr. Thomas Stoffmehl, CEO of LR Health & Beauty.
Quality has top priority for LR. The highest hygienic standards apply at the production site. The tanks used for the production of the Aloe Vera Drinking Gels are manufactured individually; there are no ready-made solutions here. The dimensions are huge. Each of the three high-tech containers is 6.5 metres high with a capacity of 39,000 litres. The machinery corresponds to the latest state of the art.
Another highlight of the new building is the so-called skywalk. A 40-metre-long walkway will be built on the first floor which runs in parallel to the production rooms. It will be glazed on one side so that visitors can follow the individual production steps live – from blending through to filling of the bottles and packaging. “This serves to reinforce our claim ‘Made in Germany’ with highest quality standards which become tangible for our LR sales partners through our transparent production,” explains Dr. Thomas Stoffmehl.
LR Health & Beauty
Under the motto “More quality for
your life“, the LR Group with headquarters in Ahlen/Westphalia produces
and markets various health and beauty products in around 28 countries.
The range includes care and decorative cosmetics, dietary supplements
and perfumes. In the fragrance segment, the company, which was founded
in 1985, has established exclusive cooperations with celebrities such as
Guido Maria Kretschmer, Karolina Kurkova and Bruce Willis. With 1,200
employees as well as thousands of registered sales partners and
customers, LR is one of Europe’s leading direct sales enterprises. LR's
strong market position is based above all on a high-quality product
range and an attractive bonus and training plan which is unsurpassed in
the industry. LR also established the LR Global Kids Fund e. V. which
provides efficient and unbureaucratic support for deprived children and
their families in many different countries around the world in
cooperation with local institutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170904005020/en/
Contact information
LR Health & Beauty
Almut Kellermeyer
Head of PR /
Public Affairs
Tel: +49 2382 70 60 114
Email: a.kellermeyer@LRworld.com
or
impact
Agentur für Kommunikation GmbH
Mieke Meimbresse
Tel. + 49
69 955264-33
Email: m.meimbresse@impact.ag
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend30.4.2025 09:00:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalificat
SES: Q1 2025 Results30.4.2025 08:30:00 EEST | Press release
SES S.A. announces financial results for the three months ended 31 March 2025. Revenue of €509 million (-0.5% yoy(1)) and Adjusted EBITDA(2) of €280 million (-0.9% yoy(1)), both growing excl. periodic impact Networks revenue up +8.4% yoy(1) including some periodic impact supported by growth in Government (+13.1% yoy(1)) and Mobility (+8.5% yoy(1)); Media (-10.6% yoy(1)) in-line with expectations €360 million of new business and contract renewals signed in Q1 2025 Net Leverage at 1.2x(3) (including cash & cash equivalents of €3.1 billion(4)) O3b mPOWER satellites 7&8 have reached final orbital position – boosting mPower network capacity and resilience from May FY 2025 financial outlook(5) on track with yoy stable Revenue and broadly stable Adjusted EBITDA re-affirmed Fully funded Intelsat acquisition anticipated to complete in H2 2025 – intention to optimise the combined debt structure On 3 April 2025, AGM approved all company recommended resolutions including prioritisation of sharehol
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 04:00:00 EEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 23:03:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2025: Sales were $1.01 billion, flat in US dollars and up 2 percent in constant currency, compared
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 22:32:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom